This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
News|Articles|August 28, 2024
Tried and True: Exploring Metformin’s Potential for Geographic Atrophy
Author(s)Connor Iapoce
A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.
Advertisement
Advertisement
Across the continuously evolving world of medicine, true breakthroughs remain rare, but when they happen, they can turn a light at the end of the tunnel into a beacon of hope. For patients battling the relentless advance of
Related to this article
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Advertisement
Advertisement